Biocon Limited has received a credit rating reaffirmation from CRISIL Ratings Limited, maintaining its strong creditworthiness profile. The pharmaceutical company informed stock exchanges about this development as part of its regulatory disclosure obligations under SEBI regulations.

Credit Rating Details

CRISIL has reaffirmed Biocon's credit ratings across its bank facilities, demonstrating confidence in the company's financial stability and repayment capacity. The rating action covers the company's total bank loan facilities of ₹250.00 crores.

Regulatory Compliance

The rating reaffirmation was disclosed pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulation mandates listed companies to inform stock exchanges about material events that could impact investor decisions.

Biocon has made the rating information available on both CRISIL's official website and the company's corporate website at www.biocon.com , ensuring transparency and easy access for stakeholders.

Significance of Rating Reaffirmation

The CRISIL AA/Stable rating indicates high safety regarding timely servicing of financial obligations, with very low credit risk. The stable outlook suggests that the rating is unlikely to change in the near term. The A1+ short-term rating reflects the highest degree of safety regarding timely payment of short-term debt obligations.

This rating reaffirmation reinforces Biocon's strong financial position in the pharmaceutical sector and provides confidence to lenders and investors about the company's creditworthiness and ability to meet its financial commitments.

Biocon Limited has announced the launch of its Glucagon-like Peptide-1 (GLP-1) drug Liraglutide in the Netherlands following approval from the Dutch Medicines Evaluation Board (MEB), marking a significant expansion of the company's peptide portfolio in European markets. This launch represents Biocon's first entry into the European Union market with Liraglutide under its own brand names.

Product Launch Details

Biocon has partnered with Pharmamedicb B.V. as its distribution partner to introduce the drug-device combination for two key therapeutic areas in the Netherlands.

Therapeutic Applications

Liraglutide will serve dual therapeutic purposes in the Dutch market:

1. For diabetes management: Marketed as gVictoza under the brand name Diavorin®.
2. For obesity treatment: Available as gSaxenda under the brand name Vobexoryn® for chronic weight management.

Strategic Significance

This launch is a significant milestone in Biocon's global expansion strategy. It showcases the company's vertically integrated, end-to-end capabilities that enable it to deliver high-quality, affordable metabolic treatments at scale. The introduction of Liraglutide in the Netherlands demonstrates Biocon's scientific and manufacturing excellence while underlining its commitment to broadening access to advanced therapies for diabetes and obesity.

About GLP-1 and Liraglutide

Glucagon-like peptide-1 (GLP-1) medications help lower blood sugar levels and promote weight loss. These physiological hormones have multiple actions on glucose, mediated by GLP-1 receptors released from gut enteroendocrine cells. They control meal-related glycemic excursions through augmentation of insulin and inhibition of glucagon secretion.

Liraglutide also inhibits gastric emptying and food intake actions, maximizing nutrient absorption while limiting weight gain. The drug was approved by the US FDA in 2014 and by the EMA a year later for adults who are either obese or overweight with at least one weight-related condition.

Distribution Partnership

Pharmamedicb B.V., Biocon's distribution partner for the Netherlands launch, is a leading supplier of generic drugs in the Dutch market. The company leverages its extensive knowledge of local market dynamics to source high-quality generic medicines. Pharmamedicb focuses on unique and specialized products within niche segments and acts as a bridge between international manufacturers and Dutch healthcare providers.

This launch marks an important step for Biocon in expanding its presence in the European market and reinforces its position as a global player in the biopharmaceutical industry.